GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Champions Oncology
Champions Oncology is a unique contract research organization (CRO) that uses patient-derived tumor models to test cancer drugs. Its stock price reflects pharmaceutical companies' demand for personalized medicine.
Share prices of companies in the market segment - Cancer cure
Champions Oncology provides preclinical and clinical research services for oncology developments using its platform of patient-derived tumor models. We classify it as part of the "Cancer Treatment" sector. The chart below shows the dynamics of this bio-service segment.
Broad Market Index - GURU.Markets
Champions Oncology is a contract research organization (CRO) that provides preclinical research services to oncology companies using its unique platform. As a significant player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Champions' performance.
Change in the price of a company, segment, and market as a whole per day
CSBR - Daily change in the company's share price Champions Oncology
Champions Oncology's daily share price fluctuations reflect the volatility of the oncology R&D sector. This metric measures the sensitivity of pharmaceutical companies to preclinical research expenditures, serving as a basis for analysis.
Daily change in the price of a set of shares in a market segment - Cancer cure
Champions Oncology's daily share price fluctuations reflect the volatility of the oncology R&D sector. This metric, a measure of pharmaceutical companies' sensitivity to preclinical research spending, serves as a basis for analysis.
Daily change in the price of a broad market stock, index - GURU.Markets
Champions Oncology provides services for oncology research, helping test drugs on tumor models. Its business reflects the level of R&D activity in the pharmaceutical industry. Its stock price is an indicator of innovation activity, influencing the overall market environment.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Champions Oncology
Champions Oncology's year-over-year performance tells the story of its unique role in personalized medicine. Its 12-month market cap growth reflects pharmaceutical companies' demand for its "avatar" platform—mice implanted with patient tumors that are used to test the effectiveness of new cancer drugs.
Annual dynamics of market capitalization of the market segment - Cancer cure
Champions Oncology, Inc. provides oncology research services using unique tumor models. Its business is a key component of pharmaceutical R&D. The chart below illustrates how its niche scientific expertise and reliance on research budgets impact its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Champions Oncology, which provides cancer drug development services, is a gold mine in the biotech world. Demand for its services is stable, as pharmaceutical companies spend on R&D throughout the economic cycle. Its stock price often shows smoother and more predictable growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Champions Oncology
Champions Oncology provides preclinical research services to oncology companies. Its business is dependent on pharmaceutical R&D spending. Monthly fluctuations in its value reflect the growth of its order book and demand for its unique tumor models (PDX).
Monthly dynamics of market capitalization of the market segment - Cancer cure
Champions Oncology, Inc. provides translational oncology research services using its live tumor model (avatar) platform for drug testing. Its sector dynamics, shown in the graph, reflect its R&D spending. Against this backdrop, one can appreciate how its unique platform helps pharmaceutical companies make more informed decisions in drug development.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Champions Oncology provides oncology research services, helping pharmaceutical companies test drugs. Its business depends on pharmaceutical R&D budgets. The graph will show more stable growth than that of biotech companies, but it is also sensitive to general industry funding trends rather than the market as a whole.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Champions Oncology
Champions Oncology, a company providing oncology research services to pharmaceutical companies, is a barometer of oncology R&D activity. Weekly stock performance reflects demand for its drug testing platforms, demonstrating the pace of development of new cancer treatments.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Champions Oncology provides services for oncology research, helping test drugs on tumor models. This chart compares how the market views its niche business model against the broader biotech sector, and helps us understand whether its growth is driven by general trends or demand for its unique services.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Champions Oncology provides services for oncology research. Demand in this sector is stable. The chart will show whether CSBR shares act as a defensive asset, demonstrating less volatility than the market due to consistent R&D spending in biotech.
Market capitalization of the company, segment and market as a whole
CSBR - Market capitalization of the company Champions Oncology
The chart of Champions Oncology is a financial "avatar" for cancer. The market cap of this company, which implants patients' tumors into mice to test various drugs, reflects the demand for personalized medicine. Its dynamics are a bet that pharmaceutical companies and doctors will increasingly use its models for decision-making.
CSBR - Share of the company's market capitalization Champions Oncology within the market segment - Cancer cure
Champions Oncology's market share in the oncology services sector reflects its unique niche. The company provides preclinical research services using patient-derived tumor models (avatars). Its market share reflects the value of its platform to pharmaceutical companies in the development of new cancer drugs.
Market capitalization of the market segment - Cancer cure
Champions Oncology provides preclinical research services to pharmaceutical companies. The chart below shows the overall market capitalization of the entire biotech sector. Its growth reflects R&D outsourcing and the need for more accurate drug testing models.
Market capitalization of all companies included in a broad market index - GURU.Markets
Champions Oncology provides preclinical research services for pharmaceutical companies using patient tumor models. Its market capitalization reflects its role in drug development. The chart below shows the economic weight of the research outsourcing sector.
Book value capitalization of the company, segment and market as a whole
CSBR - Book value capitalization of the company Champions Oncology
Champions Oncology's book value lies in its unique laboratories and its Patient-Derived Xenograft (PDX) tumor model bank. The chart below shows how the company is investing in this valuable scientific asset. Growth in this asset expands its ability to conduct preclinical studies for pharmaceutical companies.
CSBR - Share of the company's book capitalization Champions Oncology within the market segment - Cancer cure
Champions Oncology provides preclinical research services to pharmaceutical companies. Its unique asset is its live tumor bank. The asset share chart shows how it invests in sophisticated laboratory infrastructure, which is its main physical competitive advantage.
Market segment balance sheet capitalization - Cancer cure
Champions Oncology provides oncology research services. Its unique assets are not its manufacturing plants, but its cutting-edge laboratories and the world's largest tumor bank, PDX. It's a capital-intensive R&D business. The chart illustrates how dependent the entire bioresearch sector is on owning unique scientific assets.
Book value of all companies included in the broad market index - GURU.Markets
Champions Oncology's assets are not drugs, but a unique platform of "avatars"—mice implanted with patient tumors to test the drug's effectiveness. The book value reflects the capital invested in this complex model, which helps pharmaceutical companies develop cancer treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Champions Oncology
Champions Oncology provides preclinical research services for oncology companies using a unique patient-based tumor platform. Its value lies not in its labs, but in this platform and data. The chart shows how the market perceives its role in accelerating the development of new cancer drugs.
Market to book capitalization ratio in a market segment - Cancer cure
Champions Oncology provides oncology research services to pharmaceutical companies. Its unique asset is its Patient-Derived Xenograft (PDX) tumor model bank. The chart shows how highly the market values this intangible scientific asset, which is key to its business.
Market to book capitalization ratio for the market as a whole
Champions Oncology provides preclinical research services to pharmaceutical companies using unique tumor models. The chart shows how the market values this service business, which accelerates drug development. Its value lies in its scientific platform, not its assets, which allows it to command a high valuation from investors.
Debts of the company, segment and market as a whole
CSBR - Company debts Champions Oncology
Champions Oncology provides preclinical research services to pharmaceutical companies using its unique tumor model platform. The debt can be used to expand laboratory capacity and acquire new technologies to enhance its research platform.
Market segment debts - Cancer cure
Champions Oncology provides preclinical research services to oncology companies using its live tumor model platform. It is a unique service business in the biotech sector. This chart shows industry financial standards, allowing one to assess how the company is funding the expansion of its laboratories and technology platform to serve its pharmaceutical clients.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Champions Oncology
Champions Oncology provides preclinical research services to pharmaceutical companies using unique tumor models. It's a research-intensive service business. This chart shows how the company is funding its expansion and technology. Debt levels may indicate investments in new labs or acquisitions of competitors.
Market segment debt to market segment book capitalization - Cancer cure
Champions Oncology's preclinical cancer research services are a key part of the pharmaceutical ecosystem. This chart shows the debt burden in the life sciences sector. It allows us to assess how this service company's financial model differs from the biotech companies it serves and how it is funding its expansion.
Debt to book value of all companies in the market
Champions Oncology provides oncology research services using unique tumor models. It's a knowledge-intensive service business. The chart shows how their model, which requires investment in laboratories and technology, utilizes debt compared to other innovative companies and the market as a whole.
P/E of the company, segment and market as a whole
P/E - Champions Oncology
This metric for Champions Oncology, a company providing services for preclinical oncology research, reflects its unique niche. The chart shows how investors assess the demand for its tumor models from pharmaceutical companies, which use them to test new cancer drugs.
P/E of the market segment - Cancer cure
This chart shows the average valuation for pharmaceutical research services companies like Champions Oncology. This metric reflects how investors generally view the prospects of the R&D outsourcing sector. It helps understand how the market values Champions Oncology's unique niche.
P/E of the market as a whole
Champions Oncology provides oncology research services using its platform of living tumor models (avatars) for drug testing. This helps pharmaceutical companies make R&D decisions. This chart shows the mood in the biotech industry. It helps understand whether Champions Oncology is considered a valuable service partner for the entire oncology industry, with stable demand.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Champions Oncology
Champions Oncology provides preclinical research services to pharmaceutical companies using its unique platform of patient-derived tumor models. The company's future growth depends on outsourcing its oncology R&D. This chart shows how the market values its ability to help develop more effective cancer drugs, accelerating their development and reducing costs.
%20P%2FE%20Champions%20Oncology&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Champions-Oncology&v=1772639188119 "Chart of the company's future (projected) P/E Champions Oncology")
Future (projected) P/E of the market segment - Cancer cure
Champions Oncology provides services for oncology research. The company creates patient tumor avatars (PDX models) to test the effectiveness of various drugs. This is an important tool for personalized medicine. The chart reflects expectations for the biotech sector, helping to assess how the market values this unique service model.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772639188157 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Champions Oncology provides cancer research services using its platform of living tumor models (avatars) to test drug efficacy. This chart of general expectations reflects sentiment in the biotech sector. Market optimism is driving investment in the development of new anticancer drugs, increasing demand for Champions Oncology's services from pharmaceutical companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772639188209 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Champions Oncology
Champions Oncology provides preclinical research services for oncology companies using its live tumor model (avatar) platform. This chart shows growth in the pharmaceutical research outsourcing sector. Revenue depends on the number of contracts with biopharmaceutical companies that use its models to test their drugs.
Profit of companies in the market segment - Cancer cure
Ashford Hospitality Trust is a hotel REIT investing in full-service hotels. Its profitability is directly dependent on the state of the hospitality industry, including business travel and tourism. This chart reflects the hotel industry's high sensitivity to economic cycles, where revenue growth during booms can be followed by significant losses during downturns.
Overall market profit
Champions Oncology provides oncology research services to pharmaceutical companies using its live tumor model platform. This helps accelerate the development of new anti-cancer drugs. The company's business grows in line with investment in oncology research, making it resilient to economic cycles.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Champions Oncology
Champions Oncology provides preclinical oncology research services to pharmaceutical companies using a unique platform of patient-derived tumor models. Its revenue projections are dependent on R&D spending in the pharmaceutical industry. This chart shows how analysts estimate the demand for outsourced research to develop new anticancer drugs.
%20profit%20of%20the%20company%20Champions%20Oncology&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Champions-Oncology&v=1772639188387 "Graph of future (projected) profit of the company Champions Oncology")
Future (predicted) profit of companies in the market segment - Cancer cure
Champions Oncology provides preclinical research services for pharmaceutical companies using its platform of living tumor models (avatars). This helps select the most promising drug candidates. This graph shows profitability forecasts for the oncology sector. It reflects the trend toward personalization and increased efficiency in drug development.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772639188395 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Champions Oncology provides cancer research services to pharmaceutical companies using patient-derived tumor models. Demand for its services depends on R&D budgets in the pharmaceutical industry. This corporate profit projection chart helps assess the financial health of potential clients and their willingness to invest in outsourced oncology research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772639188498 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Champions Oncology
Champions Oncology provides services for oncology research, including creating "avatars" of patient tumors in mice to test the effectiveness of various drugs. Its revenue depends on pharmaceutical companies' R&D spending. The chart shows how the market values this unique model, which helps personalize cancer treatment and accelerate drug development.
P/S market segment - Cancer cure
Champions Oncology, Inc. is a contract research organization (CRO) that provides preclinical and clinical research services for oncology drugs using its unique Patient-Derived Xenograft (PDX) platform. This chart shows the average market valuation for Champions Oncology's scientific platform.
P/S of the market as a whole
Champions Oncology provides services for oncology research, specifically creating patient tumor avatars (PDX models) for drug efficacy testing. This chart helps assess the market's willingness to value the company's revenue, providing unique services that accelerate the development of new cancer treatments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Champions Oncology
Champions Oncology provides preclinical research services for oncology drugs using its unique mouse tumor models. This chart shows how the market estimates the company's future revenue. It reflects expectations for rising R&D spending in the pharmaceutical industry and demand for its specialized research services.
%20P%2FS%20Champions%20Oncology&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Champions-Oncology&v=1772639188846 "The graph of the company's future (projected) P/S Champions Oncology")
Future (projected) P/S of the market segment - Cancer cure
Champions Oncology provides preclinical research services to pharmaceutical companies using its platform of living tumor models (avatars). This helps predict drug efficacy. The chart shows how the market estimates Champions Oncology's future revenue, reflecting the demand for personalized approaches in cancer drug development.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772639188956 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
This graph reflects the trend toward personalized medicine in oncology. Champions Oncology offers a unique service: they implant patients' tumors into mice to test various drugs and select the most effective one. The demand for their services from pharmaceutical companies and clinics demonstrates how cancer research is becoming increasingly personalized.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772639189073 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Champions Oncology
Champions Oncology provides oncology research services using its unique platform of patient-derived tumor models. The company's revenue is generated through contracts with pharmaceutical companies, which use its models to test their drugs. This chart reflects R&D spending in global oncology.
Sales of companies in the market segment - Cancer cure
Champions Oncology provides preclinical research services to pharmaceutical companies using its unique "avatar" platform—mice implanted with patient tumors. This chart shows total revenue in the targeted oncology sector. It reflects the pharmaceutical industry's need for more accurate models for testing new drugs, which Champions addresses.
Overall market sales
Champions Oncology provides oncology research services to pharmaceutical companies using its platform of living tumor models (patient avatars). This facilitates the development of new drugs. Demand for its services depends on the volume of R&D in the pharmaceutical industry. This overall economic performance chart reflects the investment in oncology research that fuels the company's business.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Champions Oncology
Champions Oncology provides preclinical research services to pharmaceutical companies using a unique patient tumor avatar (PDX) platform. Its revenue is driven by oncology R&D expenditures. The chart shows analyst forecasts for the growth of the contract cancer research market.
%20sales%20of%20the%20company%20Champions%20Oncology&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Champions-Oncology&v=1772639189166 "Schedule of future (projected) sales of the company Champions Oncology")
Future (projected) sales of companies in the market segment - Cancer cure
Champions Oncology provides preclinical oncology research services to pharmaceutical companies using its patient tumor avatar platform. This helps test drug efficacy. This chart shows projected revenues for the entire oncology sector, providing an overview of overall R&D spending expectations for cancer drug development.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772639189172 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Champions Oncology provides oncology research services to pharmaceutical companies using its live tumor model platform. Demand for its services directly depends on the volume of R&D in the global pharmaceutical industry. This chart provides an overview of the overall investment climate, which determines how much pharmaceutical companies invest in preclinical research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772639189199 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Champions Oncology
Champions Oncology provides preclinical research services to pharmaceutical companies using its unique tumor models. This metric reflects the profitability of its scientific services. It shows what percentage of revenue from contracts with pharma giants the company converts into net profit, demonstrating the value of its platform.
Market segment marginality - Cancer cure
Champions Oncology provides preclinical research services to pharmaceutical companies using its unique tumor model platform. Profitability is determined by the number of contracts and the effectiveness of its research platform. This metric demonstrates the operating profitability of this service-based business model in oncology.
Market marginality as a whole
Champions Oncology provides oncology research services to pharmaceutical companies using its platform of living tumor models (avatars). This helps predict drug efficacy. This overall profitability curve impacts them through their clients' R&D budgets. When pharmaceutical companies are profitable, they invest more in preclinical research.
Employees in the company, segment and market as a whole
Number of employees in the company Champions Oncology
Champions Oncology provides preclinical research services to oncology pharmaceutical companies using its unique tumor model platform. This chart shows the size of its scientific team. The growth in the number of scientists and laboratory technicians is directly related to the increase in contracts from clients testing their new cancer drugs.
Share of the company's employees Champions Oncology within the market segment - Cancer cure
Champions Oncology provides preclinical research services for oncology drugs based on unique tumor models. This chart shows the percentage of scientists and technicians the company employs in the personalized oncology model niche. Its team helps pharmaceutical companies select the most promising drugs.
Number of employees in the market segment - Cancer cure
Champions Oncology, Inc. provides preclinical oncology research services using its live tumor model (avatar) platform. This chart shows overall employment in the cancer treatment sector. It illustrates how Champions Oncology helps pharmaceutical companies test drugs in models that closely resemble real tumors.
Number of employees in the market as a whole
Champions Oncology provides preclinical and clinical research services for pharmaceutical companies using its live tumor model (avatar) platform. This helps accelerate drug development. This graph illustrates the labor market, where scientific service companies like Champions create jobs for scientists and technicians, serving as a vital part of the R&D ecosystem.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Champions Oncology (CSBR)
Champions Oncology provides preclinical and clinical research services for oncology developments. This chart shows how the market values this knowledge-intensive service business. The high market capitalization per employee suggests that the company's value lies in its unique platform, databases, and scientific expertise, rather than its large staff.
%20of%20the%20company%20Champions%20Oncology%20(CSBR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Champions-Oncology-CSBR&v=1772639189440 "Chart of market capitalization per employee (in thousands of dollars) of the company Champions Oncology (CSBR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Champions Oncology provides oncology research services using proprietary tumor models. It's a knowledge-intensive service business. This metric reflects the value of their unique platform and expertise. A high metric indicates that their services are in high demand in the pharmaceutical industry and enable a small team of scientists to generate significant revenue.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772639189467 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Champions Oncology provides preclinical research services to pharmaceutical companies using unique tumor models grown in mice. It's a knowledge-intensive service business. Its per-employee salaries reflect the value of its unique platform and expertise, which help drug developers make more informed decisions.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772639189503 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Champions Oncology (CSBR)
Champions Oncology is a contract research organization (CRO). They help pharmaceutical companies test their oncology drugs using unique tumor models (PDX). It's a knowledge-intensive service business. This chart shows how much net profit each scientist and technician generates through contract work.
%20Chart%20Champions%20Oncology%20(CSBR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Champions-Oncology-CSBR&v=1772639189551 "Company Profit Per Employee (in thousands of dollars) Chart Champions Oncology (CSBR)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Champions Oncology provides preclinical research services to pharmaceutical companies. In this scientific service business, this metric is key. The schedule sets the bar. CSBR's effectiveness lies in its scientists' ability to conduct multiple studies on their unique tumor models, maximizing revenue from each client and each project.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772639189563 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Champions Oncology (CSBR) is a cost-recovery organization (CRO) that helps pharmaceutical companies test their cancer drugs, primarily using patient "avatars" (tumors grown in mice). This metric reflects the profitability of their scientific service, showing how much revenue each scientist generates by conducting research for their clients.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772639189575 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Champions Oncology (CSBR)
This chart for Champions Oncology, a preclinical cancer research provider, demonstrates the value of its scientific platform. The growth in revenue per employee reflects demand from pharmaceutical companies for its unique tumor models for drug testing.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Champions-Oncology-CSBR&v=1772639189603 "Sales chart per company employee Champions Oncology (CSBR)")
Sales per employee in the market segment - Cancer cure
Champions Oncology is a contract research organization (CRO) providing oncology R&D services, specifically using patient-derived tumor models (PDX). This is a scientific service. This metric reflects the average revenue per employee in the segment. It helps assess how productive their labs and scientists are in providing services to pharmaceutical companies.
Sales per employee for the market as a whole
Champions Oncology (CSBR) provides preclinical research (CRO) services to pharmaceutical companies using its unique tumor models (PDX). This metric reflects the efficiency of their laboratories. The growth in revenue per employee (scientist) indicates high demand for their specialized R&D outsourcing services and the company's ability to conduct more complex studies.
Short shares by company, segment and market as a whole
Shares shorted by company Champions Oncology (CSBR)
Champions Oncology provides preclinical research services (CRO) to oncology companies using its tumor avatar platform. This business relies on biotech R&D budgets. This chart reflects investor bets that slowing funding in the biotech sector will lead to a reduction in its research services spending.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Champions-Oncology-CSBR&v=1772639189677 "Short Shares Chart for the Company Champions Oncology (CSBR)")
Shares shorted by market segment - Cancer cure
Champions Oncology (CSBR) provides oncology research services, including the creation of personalized tumor models (PDX models) for drug testing. This chart shows the overall short position in the contract research organization (CRO) sector. It reflects market sentiment regarding R&D budgets among biotech and pharmaceutical companies.
Shares shorted by the overall market
Champions Oncology (CSBR) is a CRO that tests drugs for biotechs. Its business is a "shovel" for R&D. When this chart shows rising fear, it signals a "venture winter." This means that CSBR's clients (small biotechs) are freezing R&D, which is hurting orders.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Champions Oncology (CSBR)
Champions Oncology (CSBR) is the "pick and shovel" of oncology. They provide CRO services by testing pharmaceutical companies' drugs on "avatars" (patient tumors implanted in mice). This chart measures how the market values biotech R&D budgets. It shows peaks of optimism (overbought) and troughs (oversold).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Champions-Oncology-CSBR&v=1772639189766 "RSI 14 indicator chart for the company's stock Champions Oncology (CSBR)")
RSI 14 Market Segment - Cancer cure
Champions (CSBR) are the "mice" of biotech. They *don't* cure, but *provide* (CRO) *models* (PDX - "mice with human tumors") for *testing* cancer drugs. The "Cancer Cure" sector (biotech/CRO) thrives on R&D. RSI_14_Seg shows the "temperature" of the *entire* industry. It helps us understand: is CSBR's growth a niche or a general "hype"?
RSI 14 for the overall market
Champions Oncology (CSBR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CSBR (Champions Oncology)
Champions Oncology is a CRO (contract research organization) that helps pharmaceutical companies test their cancer drugs on "avatars"—mice transplanted with live tumors from patients. This chart shows the average price target from analysts estimating the growth in demand for this unique R&D service.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CSBR-Champions-Oncology&v=1772639189826 "A chart showing analyst consensus forecasts for the expected stock price. CSBR (Champions Oncology)")
The difference between the consensus estimate and the actual stock price CSBR (Champions Oncology)
CSBR - Champions Oncology is not a drug developer, but a CRO. It uses patients' tumors to create "avatars" (mice) on which to test drugs for Big Pharma. This chart clearly demonstrates the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in R&D outsourcing.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CSBR-Champions-Oncology&v=1772639189835 "A chart showing the difference between the consensus forecast and the actual stock price. CSBR (Champions Oncology)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Champions Oncology (CSBR) is a contract research organization (CRO) that uses a unique "avatar" platform (patient tumors implanted in mice) to test drugs. This chart shows general expectations for the cancer treatment sector. It reflects whether experts believe there will be growth in oncology R&D outsourcing.
Analysts' consensus forecast for the overall market share price
Champions Oncology is a contract research organization (CRO) that provides a unique service: they "grow" patient tumors in mice (avatars) to test drugs on them. This chart shows the overall market sentiment. For Champions, which operates behind the scenes in the defense pharmaceutical sector, the overall optimism is important because it reflects the size of the R&D budgets of the biotech companies that are their clients.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Champions Oncology
Champions Oncology (CSBR) is a biotech service company (CRO). Their specialty is avatars (PDX): they implant real patient tumors into mice and test drugs on them to see what works. This graph is their R&D pick and shovel. It measures their ability to sell this premium service (mouse testing) to pharmaceutical companies developing new drugs.
AKIMA Market Segment Index - Cancer cure
Champions Oncology provides oncology R&D services, specifically by growing patient tumors in mice (PDX models) for drug testing. This chart shows the average index for the oncology sector. It helps investors assess the effectiveness of Champions Oncology's B2B model (pharma shovels).
The AKIM Index for the overall market
Champions Oncology is a company providing cutting-edge technological solutions (mouse avatar models) for personalized oncology and drug development. This chart, reflecting the market average, is a backdrop. It helps assess how this service business for the pharmaceutical industry, which accelerates R&D, compares against the backdrop of overall macroeconomic fluctuations.
